<![CDATA[PulvinarNeuro - Newsroom]]>Fri, 21 Aug 2026 16:05:43 -0400Weebly<![CDATA[Pulvinar Neuro awarded $3 million nih grant for transcranial stimulation research]]>Fri, 19 May 2023 18:23:33 GMThttp://www.pulvinarneuro.com/newsroom/pulvinar-neuro-awarded-3-million-nih-grant-for-transcranial-stimulation-researchPulvinar Neuro is both honored and thrilled to share that we have been awarded a three-year, $3.06 million Phase II SBIR Grant from the NIH's National Institute of Mental Health (NIMH). 

For more information, please click here.]]><![CDATA[Pulvinar Neuro to Attend 5th International Brain Stimulation COnference]]>Wed, 01 Feb 2023 05:00:00 GMThttp://www.pulvinarneuro.com/newsroom/pulvinar-neuro-to-attend-5th-international-brain-stimulation-conferencePulvinar Neuro, in partnership with Electromedical Products International, Inc. (EPI), is excited to announce that Dr. Leah Townsend, President of Pulvinar Neuro and Chief Science Officer of EPI, will be attending the 5th International Brain Stimulation Conference in Lisbon, Portugal (Saturday, February 18, 2023 - Wednesday, February 22, 2023). Dr. Townsend will have Pulvinar's next-generation research device, XCSITE-RD at Booth #29.

Stop by if you're attending to meet Dr. Townsend and discuss the future of non-invasive brain stimulation in psychiatry!]]><![CDATA[Pulvinar Neuro Partners with EPI]]>Tue, 01 Mar 2022 05:00:00 GMThttp://www.pulvinarneuro.com/newsroom/pulvinar-neuro-partners-with-epi
Picture
Flavio Frohlich, PhD, associate professor, UNC Neuroscience Center, and Founder of Pulvinar Neuro, and Leah Townsend, PhD, CEO of Pulvinar Neuro
We are excited to announce a strategic partnership with Electromedical Products International, Inc. (EPI), a leading medical device company using non-invasive brain stimulation to treat psychiatric disorders. This partnership will allow us to accelerate our non-invasive brain stimulation and product development, including transcranial alternating current stimulation (tACS), individualized feedback stimulation, and cloud-enabled therapeutics for the treatment of psychiatric and neurological illnesses.
I am looking forward to working with EPI to bring the next generation of personalized non-invasive brain stimulation to market, complementary with EPI's suites of devices, which we are confident will benefit millions of patients who are looking for effective and safe treatment options.
-Dr. Leah Townsend, President of Pulvinar Neuro
EPI is the market leader in low-current, non-invasive brain stimulation and has a long-standing track record of marketing its patented, FDA-cleared Alpha-Stim technology for the treatment of anxiety, insomnia, depression, and pain. 
Closed-loop low-intensity transcranial stimulation for the treatment of CNS disorder has a very bright future ahead.
-Dr. Flavio Frohlich, Founder of Pulvinar Neuro
]]><![CDATA[Meet New CEO: Dr. Leah Townsend, PhD]]>Sun, 01 Sep 2019 04:00:00 GMThttp://www.pulvinarneuro.com/newsroom/meet-new-ceo-dr-leah-townsend-phdWe are pleased to announce that Dr. Leah Townsend, PhD has joined us as Chief Executive Officer of Pulvinar Neuro. She previously served as a business consultant for Pulvinar Neuro and was instrumental in winning our Phase I NIMH grant (R43MH119872) to develop closed-loop tACS.
​Dr. Townsend has a broad foundation in life sciences research and consulting, with over 10 years of experience in human physiology and disease pathology in addition to neurobiology. She has previous experience in both business development and life science consulting including advising life science and biotechnology clients in areas including commercial assessment and strategy, portfolio optimization, and search-based asset identification in therapeutic areas including neurology, gene therapy, stem cell therapy, oncology, bacterial infections, cardiovascular, and rare disease.
Dr. Townsend holds a PhD in Neurobiology from the University of North Carolina at Chapel Hill (UNC-CH) as well as both a BS in Psychology (summa cum laude) and BA in Philosophy (cum laude), also from UNC- CH.
]]>